香港股市 將在 2 小時 29 分鐘 開市
  • 恒指

    22,688.90
    +122.10 (+0.54%)
     
  • 國指

    7,773.61
    +66.89 (+0.87%)
     
  • 上證綜指

    3,264.81
    +24.53 (+0.76%)
     
  • 道指

    33,978.08
    +28.68 (+0.08%)
     
  • 標普 500

    4,070.56
    +10.13 (+0.25%)
     
  • 納指

    11,621.71
    +109.31 (+0.95%)
     
  • Vix指數

    18.51
    -0.22 (-1.17%)
     
  • 富時100

    7,765.15
    +4.04 (+0.05%)
     
  • 紐約期油

    79.38
    -0.30 (-0.38%)
     
  • 金價

    1,943.90
    -1.70 (-0.09%)
     
  • 美元

    7.8294
    +0.0015 (+0.02%)
     
  • 人民幣

    0.8659
    0.0000 (0.00%)
     
  • 日圓

    0.0600
    +0.0002 (+0.28%)
     
  • 歐元

    8.5075
    -0.0147 (-0.17%)
     
  • Bitcoin

    23,750.65
    +739.20 (+3.21%)
     
  • CMC Crypto 200

    526.66
    +9.65 (+1.87%)
     

Labcorp Forecasts Steeper Fall In COVID-19 Testing Sales

  • Laboratory Corp of America Holdings (NYSE: LH) posted Q3 revenues of $3.61 billion, a decrease of 11.2% Y/Y, missing the consensus of $3.79 billion.

  • The 10.7% decrease in organic revenue was driven by an 11.8% decrease in COVID-19 Testing, partially offset by a 1.1% increase in the company's organic Base Business.

  • "We continue to manage inflationary headwinds and labor constraints through our LaunchPad initiatives. And, we are accelerating the planned spin-off of our Clinical Development business to mid-2023 pending customary approvals," said Adam Schechter, chairman & CEO.

  • Adjusted operating margin compressed from 22.3% to 16.3%.

  • Diagnostic sales decreased 15.7% to $2.21 billion. Total volume (measured by requisitions) decreased by 10.3%.

  • The company posted an adjusted EPS of $4.68 versus $6.82 a year ago and a consensus of $4.67.

  • Guidance: Labcorp revised FY22 adjusted EPS guidance to $19.25-$20.25 compared to the prior range of $19.00-$21.25.

  • The company expects COVID-19 testing sales to decline (59.0%)-(57.0%) versus (60.0%)-(50.0%) expected earlier.

  • Price Action: LH shares are down 6.28% at $215.50 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.